Swiss drug major Roche (ROG: SIX) on Monday said late stage trials for its drug to treat primary progressive multiple sclerosis met its primary endpoint.
The company said Phase III trials showed treatment with the drug candidate, ocrelizumab, significantly reduced the progression of clinical disability sustained for at least 12 weeks compared with placebo.
Overall, the incidence of adverse effects associated with the trial drug was similar to placebo with the most common adverse events being mild-to-moderate infusion-related reactions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze